ELF regimen in advanced gastrointestinal malignancies: An analysis of its clinical effectiveness and toxicity

Giuseppe Di Gesu', Nicolo' Gebbia, Pietro Leo, Vittorio Gebbia, Carmelo Sciume', Calogero Cipolla, Curto, Verderame, Valenza, Carmelo Sciume, Cannata, Di Gesu, Testa, Fortunato, Nicola Gebbia, Vittorio Gebbia, Pietro Leo, Cusumano

Risultato della ricerca: Article

Abstract

A multi-institutional phase II study of the combination of levofolinic acid 100 mg/m2, VP16 120 mg/m2 and 5-fluorouracil 500 mg/m2 for 3 consecutive days was carried out on a series of 73 evaluable patients with low performance status affected by locally advanced and/or metastatic gastrointestinal carcinomas. Site of primary tumor were: stomach 26, large bowel 20, pancreas 16, gall-bladder 5, and liver 6. Among patients with gastric carcinoma, 2 patients (8%) had a complete response with a mean duration of 6.8+ months, for an overall response rate of 43%. Overall response rate was largely unsatisfactory in colorectal carcinoma (20%), pancreatic (12%), gall-bladder and liver carcinomas. The treatment was very well tolerated with no grade 4 toxicity over a total of 267 cycles administered. Grade 3 leukopenia was seen in 25% of cases, and grade 2 thrombocytopenia in 18%. Vomiting never exceeded grade 2. Thus, the ELF regimen is quite active in advanced gastric carcinoma, and may be recommended as palliative treatment of patients who cannot receive intensive chemotherapy. On the other hand, it cannot be considered active in colorectal, pancreatic, gall-bladder and liver carcinomas, and its use should be discouraged in these neoplasms.
Lingua originaleEnglish
pagine (da-a)411-415
Numero di pagine5
RivistaInternational Journal of Oncology
Volume4
Stato di pubblicazionePublished - 1994

Fingerprint

Carcinoma
Stomach
Urinary Bladder
Neoplasms
Liver
Leukopenia
Palliative Care
Fluorouracil
Vomiting
Pancreas
Colorectal Neoplasms
Drug Therapy
Acids
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

ELF regimen in advanced gastrointestinal malignancies: An analysis of its clinical effectiveness and toxicity. / Di Gesu', Giuseppe; Gebbia, Nicolo'; Leo, Pietro; Gebbia, Vittorio; Sciume', Carmelo; Cipolla, Calogero; Curto; Verderame; Valenza; Sciume, Carmelo; Cannata; Di Gesu; Testa; Fortunato; Gebbia, Nicola; Gebbia, Vittorio; Leo, Pietro; Cusumano.

In: International Journal of Oncology, Vol. 4, 1994, pag. 411-415.

Risultato della ricerca: Article

Di Gesu', G, Gebbia, N, Leo, P, Gebbia, V, Sciume', C, Cipolla, C, Curto, Verderame, Valenza, Sciume, C, Cannata, Di Gesu, Testa, Fortunato, Gebbia, N, Gebbia, V, Leo, P & Cusumano 1994, 'ELF regimen in advanced gastrointestinal malignancies: An analysis of its clinical effectiveness and toxicity', International Journal of Oncology, vol. 4, pagg. 411-415.
Di Gesu', Giuseppe ; Gebbia, Nicolo' ; Leo, Pietro ; Gebbia, Vittorio ; Sciume', Carmelo ; Cipolla, Calogero ; Curto ; Verderame ; Valenza ; Sciume, Carmelo ; Cannata ; Di Gesu ; Testa ; Fortunato ; Gebbia, Nicola ; Gebbia, Vittorio ; Leo, Pietro ; Cusumano. / ELF regimen in advanced gastrointestinal malignancies: An analysis of its clinical effectiveness and toxicity. In: International Journal of Oncology. 1994 ; Vol. 4. pagg. 411-415.
@article{ce14efaec11a4cd895ba2c23bbcb869d,
title = "ELF regimen in advanced gastrointestinal malignancies: An analysis of its clinical effectiveness and toxicity",
abstract = "A multi-institutional phase II study of the combination of levofolinic acid 100 mg/m2, VP16 120 mg/m2 and 5-fluorouracil 500 mg/m2 for 3 consecutive days was carried out on a series of 73 evaluable patients with low performance status affected by locally advanced and/or metastatic gastrointestinal carcinomas. Site of primary tumor were: stomach 26, large bowel 20, pancreas 16, gall-bladder 5, and liver 6. Among patients with gastric carcinoma, 2 patients (8{\%}) had a complete response with a mean duration of 6.8+ months, for an overall response rate of 43{\%}. Overall response rate was largely unsatisfactory in colorectal carcinoma (20{\%}), pancreatic (12{\%}), gall-bladder and liver carcinomas. The treatment was very well tolerated with no grade 4 toxicity over a total of 267 cycles administered. Grade 3 leukopenia was seen in 25{\%} of cases, and grade 2 thrombocytopenia in 18{\%}. Vomiting never exceeded grade 2. Thus, the ELF regimen is quite active in advanced gastric carcinoma, and may be recommended as palliative treatment of patients who cannot receive intensive chemotherapy. On the other hand, it cannot be considered active in colorectal, pancreatic, gall-bladder and liver carcinomas, and its use should be discouraged in these neoplasms.",
keywords = "Colorectal cancer; ELF regimen; Etoposide; Fluorouracil; Folinic acid; Gall-bladder cancer; Gastric cancer; Liver cancer; Pancreatic cancer; Cancer Research; Oncology",
author = "{Di Gesu'}, Giuseppe and Nicolo' Gebbia and Pietro Leo and Vittorio Gebbia and Carmelo Sciume' and Calogero Cipolla and Curto and Verderame and Valenza and Carmelo Sciume and Cannata and {Di Gesu} and Testa and Fortunato and Nicola Gebbia and Vittorio Gebbia and Pietro Leo and Cusumano",
year = "1994",
language = "English",
volume = "4",
pages = "411--415",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",

}

TY - JOUR

T1 - ELF regimen in advanced gastrointestinal malignancies: An analysis of its clinical effectiveness and toxicity

AU - Di Gesu', Giuseppe

AU - Gebbia, Nicolo'

AU - Leo, Pietro

AU - Gebbia, Vittorio

AU - Sciume', Carmelo

AU - Cipolla, Calogero

AU - Curto, null

AU - Verderame, null

AU - Valenza, null

AU - Sciume, Carmelo

AU - Cannata, null

AU - Di Gesu, null

AU - Testa, null

AU - Fortunato, null

AU - Gebbia, Nicola

AU - Gebbia, Vittorio

AU - Leo, Pietro

AU - Cusumano, null

PY - 1994

Y1 - 1994

N2 - A multi-institutional phase II study of the combination of levofolinic acid 100 mg/m2, VP16 120 mg/m2 and 5-fluorouracil 500 mg/m2 for 3 consecutive days was carried out on a series of 73 evaluable patients with low performance status affected by locally advanced and/or metastatic gastrointestinal carcinomas. Site of primary tumor were: stomach 26, large bowel 20, pancreas 16, gall-bladder 5, and liver 6. Among patients with gastric carcinoma, 2 patients (8%) had a complete response with a mean duration of 6.8+ months, for an overall response rate of 43%. Overall response rate was largely unsatisfactory in colorectal carcinoma (20%), pancreatic (12%), gall-bladder and liver carcinomas. The treatment was very well tolerated with no grade 4 toxicity over a total of 267 cycles administered. Grade 3 leukopenia was seen in 25% of cases, and grade 2 thrombocytopenia in 18%. Vomiting never exceeded grade 2. Thus, the ELF regimen is quite active in advanced gastric carcinoma, and may be recommended as palliative treatment of patients who cannot receive intensive chemotherapy. On the other hand, it cannot be considered active in colorectal, pancreatic, gall-bladder and liver carcinomas, and its use should be discouraged in these neoplasms.

AB - A multi-institutional phase II study of the combination of levofolinic acid 100 mg/m2, VP16 120 mg/m2 and 5-fluorouracil 500 mg/m2 for 3 consecutive days was carried out on a series of 73 evaluable patients with low performance status affected by locally advanced and/or metastatic gastrointestinal carcinomas. Site of primary tumor were: stomach 26, large bowel 20, pancreas 16, gall-bladder 5, and liver 6. Among patients with gastric carcinoma, 2 patients (8%) had a complete response with a mean duration of 6.8+ months, for an overall response rate of 43%. Overall response rate was largely unsatisfactory in colorectal carcinoma (20%), pancreatic (12%), gall-bladder and liver carcinomas. The treatment was very well tolerated with no grade 4 toxicity over a total of 267 cycles administered. Grade 3 leukopenia was seen in 25% of cases, and grade 2 thrombocytopenia in 18%. Vomiting never exceeded grade 2. Thus, the ELF regimen is quite active in advanced gastric carcinoma, and may be recommended as palliative treatment of patients who cannot receive intensive chemotherapy. On the other hand, it cannot be considered active in colorectal, pancreatic, gall-bladder and liver carcinomas, and its use should be discouraged in these neoplasms.

KW - Colorectal cancer; ELF regimen; Etoposide; Fluorouracil; Folinic acid; Gall-bladder cancer; Gastric cancer; Liver cancer; Pancreatic cancer; Cancer Research; Oncology

UR - http://hdl.handle.net/10447/220513

M3 - Article

VL - 4

SP - 411

EP - 415

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

ER -